drugset / Trial / NCT03481400
CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment
RandomizedCrossoverDouble-blindOther
Summary
The investigators aim to investigate the incidence of migraine attacks after calcitonin gene-related peptide (CGRP) infusion in patients who have tried anti-CGRP monoclonal antibody treatment for the prevention of migraine.
Timeline
- Start
- 2016-07
- Primary completion
- 2019-09
- Completion
- 2019-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcitonin Gene-Related Peptide | Peptide | 1.5 ug | Intravenous |